J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 H i s t o r y
2 R e s e a r c h
3 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
E d i t a s M e d i c i n e
1 l a n g u a g e
● D e u t s c h
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Discovery-phase pharmaceutical company
Editas Medicine, Inc. , (formerly Gengine, Inc. ), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.[2] [3] Cambridge, Massachusetts and has facilities in Boulder, Colorado .[4] [5] [6]
History [ edit ]
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute , Jennifer Doudna of the University of California, Berkeley ,[7] George Church , David Liu , and J. Keith Joung of Harvard University , with funding from Third Rock Ventures , Polaris Partners and Flagship Ventures ; the name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9 .[8] [9] [10]
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors.[11] [12] [2] initial public offering that raised $94 million.[13] [14]
The company entered into a strategic collaboration with Juno Therapeutics in 2015 to combine its CRISPR-Cas9 technology with Juno's experience in creating chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics.[15] Celgene ,[16] Bristol Myers Squibb .[17]
The company announced in 2015 that it was planning a clinical trial in 2017 using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness.[18] [10] FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587).[19] [20] [21]
In March 2020, Editas, in partnership with Allergan , was the first to use CRISPR to try to edit DNA inside a person's body (in vivo intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions.[22] [23] AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.[24]
In 2019, the company was building new chemistry facilities in Boulder, Colorado .[5]
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins.[25] [26] James Mullen , who had been board chairman.[27] Sarepta Therapeutics , became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.[28]
Research [ edit ]
Editas works with two different CRISPR nucleases , Cas9 and Cas12a .[29]
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, which is currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia . In 2019 the firm reported early success in research on the drug;.[30] [31] phase 1 safety studies.[32]
References [ edit ]
^ "Editas Wins FDA Approval for IND of CRISPR Treatment for LCA10" . Genetic Engineering & Biotechnology News . 30 November 2018. Retrieved 20 August 2020 .
^ Werley, Jensen (5 September 2019). "How Boulder biotech companies are putting Colorado on the gene-editing map" . Denver Business Journal . Retrieved 27 October 2020 .
^ a b Symington, Steve (20 August 2020). "Editas Medicine Remains on Track" . The Motley Fool . Retrieved 20 August 2020 .
^ "Who We Are" . Editas Medicine . Retrieved 2022-02-25 .
^ Rockoff, Jonathan (2015-06-29). "Why Gene-Editing Technology Has Scientists Excited" . Wall Street Journal . ISSN 0099-9660 . Retrieved 2021-05-27 .
^ Isaacson, Walter (2021). The Code Breaker Simon & Schuster . pp. 209–212. ISBN 978-1-9821-1585-2
^ John Carroll (Nov 25, 2013). "Biotech pioneer in 'gene editing' launches with $43M in VC cash" . FierceBiotech.
^ a b Regalado, Antonio (2015-11-05). "CRISPR Gene Editing to Be Tested on People by 2017, Says Editas" . MIT Technology Review . Retrieved 2016-06-21 .
^ Nowogrodzki, Anna (10 August 2015). "Gene-Editing Startup Raises $120 Million to Apply CRISPR to Medicine" . MIT Technology Review . Retrieved 12 August 2020 .
^ Loria, Kevin (12 April 2018). "Bill Gates says it would be a 'tragedy' to pass up a controversial, revolutionary gene-editing technology" . Business Insider
^ Pflanzer, Lydia (2 February 2016). "A Bill Gates-backed startup that wants to edit your genes just raised nearly $100 million" . Business Insider
^ Fidler, Ben (2 February 2016). "CRISPR Hits Wall Street as Editas Bags $94M in IPO" . Xconomy . Retrieved 12 August 2020 .
^ "Juno, Editas Launch Up-to-$737M+ Cancer Therapy Collaboration" . Genetic Engineering & Biotechnology News . Retrieved 2016-02-11 .
^ Lombardo, Cara (2018-01-22). "Celgene to Buy Juno Therapeutics for $9 Billion" . Wall Street Journal . ISSN 0099-9660 . Retrieved 2018-01-22 .
^ Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company , PM BMS, November 20, 2019; retrieved May 20, 2020
^ Kuchler, Hannah (6 January 2020). "Crispr puts first human in-body gene editing to test" . Financial Times
^ "First CRISPR therapy dosed" . Nature 38 4 ): 382. 7 April 2020. doi :10.1038/s41587-020-0493-4 PMID 32265555 .
^ Sheridan, Cormac (14 December 2018). "Go-ahead for first in-body CRISPR medicine testing" . Nature doi :10.1038/d41587-018-00003-2 . S2CID 91818387 . Retrieved 21 December 2018 .
^ "Editas Medicine Announces Positive Initial Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial Of EDIT-101 For LCA10" . Editas Medicine . 29 September 2021. Archived from the original on 2021-09-29. Retrieved 5 November 2021 .
^ Stein, Rob (4 March 2020). "In A 1st, Scientists Use Revolutionary Gene-Editing Tool To Edit Inside A Patient" . NPR . Retrieved 12 August 2020 .
^ Terry, Mark (4 March 2020). "Allergan and Editas Dose First Patient in Historic CRISPR Trial for Inherited Blindness" . BioSpace . Retrieved 12 August 2020 .
^ Fidler, Ben (7 August 2020). "Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes" . BioPharma Dive . Retrieved 12 August 2020 .
^ Dearment, Alaric (22 January 2019). "Editas Medicine CEO steps down as company moves into product development stage" . MedCity News . Retrieved 12 August 2020 .
^ DeAngelis, Allison (6 August 2019). "Editas became Cindy Collins. CEO" . Boston Business Journal
^ "Editas Medicine Announces Appointment Of James C. Mullen As Chief Executive Officer" (Press release). Editas Medicine. 8 February 2021.
^ Keown, Alex (14 April 2022). "Gilmore O'Neill "Excited" to Take the Reins at Editas Medicine" . BioSpace . Retrieved 2 June 2022 .
^ Pickar-Oliver, Adrian; Gersbach, Charles A. (August 2019). "The next generation of CRISPR–Cas technologies and applications" . Nature Reviews Molecular Cell Biology . 20 8 ): 490–507. doi :10.1038/s41580-019-0131-5 . ISSN 1471-0080 . PMC 7079207 PMID 31147612 .
^ Rees, Victoria (20 June 2019). "Experimental treatment for sickle cell disease success" . Drug Target Review . Retrieved 20 August 2020 .
^ Wong, Sandi (10 December 2019). "Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia" . BioCentury . Retrieved 20 August 2020 .
^ Carvalho, Joana (21 January 2021). "FDA Clears Way for Trial of Gene Editing Therapy for Severe SCD" . Retrieved 2021-03-29 .
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Editas_Medicine&oldid=1223003759 " C a t e g o r i e s : ● 2 0 1 3 e s t a b l i s h m e n t s i n M a s s a c h u s e t t s ● 2 0 1 6 i n i t i a l p u b l i c o f f e r i n g s ● G e n o m i c s c o m p a n i e s ● P h a r m a c e u t i c a l c o m p a n i e s o f t h e U n i t e d S t a t e s ● C o m p a n i e s b a s e d i n C a m b r i d g e , M a s s a c h u s e t t s ● C o m p a n i e s l i s t e d o n t h e N a s d a q ● G e n e t h e r a p y ● H e a l t h c a r e c o m p a n i e s b a s e d i n M a s s a c h u s e t t s ● P h a r m a c e u t i c a l c o m p a n i e s e s t a b l i s h e d i n 2 0 1 3 ● B i o t e c h n o l o g y c o m p a n i e s o f t h e U n i t e d S t a t e s H i d d e n c a t e g o r i e s : ● P a g e s w i t h n o n - n u m e r i c f o r m a t n u m a r g u m e n t s ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● A r t i c l e s w i t h I S N I i d e n t i f i e r s
● T h i s p a g e w a s l a s t e d i t e d o n 9 M a y 2 0 2 4 , a t 0 8 : 0 2 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
US$19.7 million (2022)
